Clinical Trial

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

Study acronym: HCC-SIGHT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure. The study aims to rapidly identify the most effective investigational regimens and discover predictive biomarker signatures (from tumor tissue, blood, and imaging) to guide personalized second-line therapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-22
Trial Details
NCT Number NCT07328009
Lead Sponsor Fudan University
Conditions Hepato Cellular Carcinoma (HCC)
Enrollment 350 participants
Start Date 2026-01-19
Primary Completion 2029-01-15 (estimated)
Study Completion 2029-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-21